$CBDL CBD Life Sciences Inc. (CBDL) Announces LOI With New Jersey Dispensary, Unlocking New Revenue Channels & Strategic Growth Opportunities
https://www.accessnewswire.com/newsroom/en/he...ry-1076821
Strategic collaboration expands CBDL's footprint in the booming East Coast cannabis market projected to surpass $33 billion by 2030, while strengthening retail distribution and cross-brand synergies
SCOTTSDALE, AZ / ACCESS Newswire / September 23, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its wholly owned subsidiary, CBD Vault, is proud to announce that it has entered into a Letter of Intent (LOI) with a licensed dispensary in New Jersey. This powerful agreement represents not just product placement, but a transformational partnership that creates two-way retail visibility, accelerates brand recognition, and opens the door to significant new revenue streams in one of the fastest-growing cannabis markets in the United States.
A Dual-Channel Partnership for Scalable Growth
Unlike conventional wholesale agreements, this LOI establishes a mutually beneficial distribution model. Under the terms, CBD Vault's flagship products - including the Company's industry-leading CBD Pain Relief Cream, Pain Relief Roll-On, 3000mg CBD Tinctures, and Delta-8 Gummies - will secure premium shelf space inside a bustling New Jersey dispensary. In return, select products from the dispensary's proprietary line will be stocked and featured in CBDL's own retail locations, creating a cross-pollination of audiences and expanding market reach for both companies.
This two-way approach not only diversifies CBDL's product mix but also positions the Company as a true collaborative partner within the cannabis ecosystem, enhancing long-term relationships and securing recurring sales channels.
Massive Market Potential on the East Coast
New Jersey's cannabis industry is emerging as a powerhouse. Recent research projects the state's market to surpass $2 billion annually by 2026, driven by both recreational legalization and strong consumer demand. The broader U.S. CBD and cannabis sector is forecasted to reach $33 billion by 2030, with wellness-driven CBD categories alone experiencing CAGR growth rates exceeding 14%.
For CBDL, this LOI is more than regional growth - it's an entry point into the lucrative East Coast corridor, which includes high-value markets such as New York, Pennsylvania, and Massachusetts. Establishing a foothold in New Jersey provides an anchor for potential multi-state expansion and positions the Company at the forefront of national growth trends.
Revenue Impact and Shareholder Value
Management anticipates that this strategic partnership could translate into seven-figure annualized revenues, while simultaneously boosting foot traffic and customer acquisition through reciprocal product placement. The cross-distribution model also mitigates risk by ensuring exposure to two distinct but synergistic consumer bases - dispensary shoppers and CBDL's loyal retail following.
"This LOI is more than just a retail deal - it's a strategic partnership that multiplies opportunities on both ends," stated Lisa Nelson, President & CEO of CBD Life Sciences Inc. "We are not only penetrating one of the strongest cannabis markets in the country, but we're also pioneering a distribution model that enhances shareholder value and sets the stage for exponential growth. We believe this collaboration will be the first of many as we aggressively expand across the East Coast."
Expanding Beyond New Jersey
CBDL views this New Jersey collaboration as a launchpad for broader growth. The Company plans to replicate this model with additional dispensaries and retailers in high-demand markets, creating a scalable blueprint for expansion. By leveraging strong brand equity, product innovation, and investor backing, CBDL is strategically positioned to capture substantial market share as the industry continues its rapid ascent.
https://www.accessnewswire.com/newsroom/en/he...ry-1076821
Strategic collaboration expands CBDL's footprint in the booming East Coast cannabis market projected to surpass $33 billion by 2030, while strengthening retail distribution and cross-brand synergies
SCOTTSDALE, AZ / ACCESS Newswire / September 23, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its wholly owned subsidiary, CBD Vault, is proud to announce that it has entered into a Letter of Intent (LOI) with a licensed dispensary in New Jersey. This powerful agreement represents not just product placement, but a transformational partnership that creates two-way retail visibility, accelerates brand recognition, and opens the door to significant new revenue streams in one of the fastest-growing cannabis markets in the United States.
A Dual-Channel Partnership for Scalable Growth
Unlike conventional wholesale agreements, this LOI establishes a mutually beneficial distribution model. Under the terms, CBD Vault's flagship products - including the Company's industry-leading CBD Pain Relief Cream, Pain Relief Roll-On, 3000mg CBD Tinctures, and Delta-8 Gummies - will secure premium shelf space inside a bustling New Jersey dispensary. In return, select products from the dispensary's proprietary line will be stocked and featured in CBDL's own retail locations, creating a cross-pollination of audiences and expanding market reach for both companies.
This two-way approach not only diversifies CBDL's product mix but also positions the Company as a true collaborative partner within the cannabis ecosystem, enhancing long-term relationships and securing recurring sales channels.
Massive Market Potential on the East Coast
New Jersey's cannabis industry is emerging as a powerhouse. Recent research projects the state's market to surpass $2 billion annually by 2026, driven by both recreational legalization and strong consumer demand. The broader U.S. CBD and cannabis sector is forecasted to reach $33 billion by 2030, with wellness-driven CBD categories alone experiencing CAGR growth rates exceeding 14%.
For CBDL, this LOI is more than regional growth - it's an entry point into the lucrative East Coast corridor, which includes high-value markets such as New York, Pennsylvania, and Massachusetts. Establishing a foothold in New Jersey provides an anchor for potential multi-state expansion and positions the Company at the forefront of national growth trends.
Revenue Impact and Shareholder Value
Management anticipates that this strategic partnership could translate into seven-figure annualized revenues, while simultaneously boosting foot traffic and customer acquisition through reciprocal product placement. The cross-distribution model also mitigates risk by ensuring exposure to two distinct but synergistic consumer bases - dispensary shoppers and CBDL's loyal retail following.
"This LOI is more than just a retail deal - it's a strategic partnership that multiplies opportunities on both ends," stated Lisa Nelson, President & CEO of CBD Life Sciences Inc. "We are not only penetrating one of the strongest cannabis markets in the country, but we're also pioneering a distribution model that enhances shareholder value and sets the stage for exponential growth. We believe this collaboration will be the first of many as we aggressively expand across the East Coast."
Expanding Beyond New Jersey
CBDL views this New Jersey collaboration as a launchpad for broader growth. The Company plans to replicate this model with additional dispensaries and retailers in high-demand markets, creating a scalable blueprint for expansion. By leveraging strong brand equity, product innovation, and investor backing, CBDL is strategically positioned to capture substantial market share as the industry continues its rapid ascent.
